Andrew Sacco, OD
Optometrist · Vestal, NYNPI 1588638597
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,000 of the $1,477 with a category attached, or 67.7%. Eyevance Pharmaceuticals LLC accounts for 67.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $1,261 and has fallen 98.7% since, to $17 in 2024.
Across 13 payments — averaging $113.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyevance Pharmaceuticals LLC$1K
- Sanofi$118
- Sight Sciences, Inc.$108
- Biotissue Holdings Inc.$80
- Johnson & Johnson Vision Care, Inc.$43
- Alcon$27
- plus $101 from 6 others
Across 197 payments — averaging $10,276 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Vision Care, Inc.$1.5M
- Coopervision Inc.$234K
- Bausch & Lomb Americas Inc.$176K
- Bausch Health US, LLC$129K
- Alcon Research LLC$21K
What the payments were for
- Consulting fees$1,00068%
- Food & beverage$47732%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyevance Pharmaceuticals LLC | 1 | $1,000 |
| Sanofi | 1 | $118 |
| Sight Sciences, Inc. | 1 | $108 |
| Biotissue Holdings Inc. | 1 | $80 |
| Johnson & Johnson Vision Care, Inc. | 1 | $43 |
| Alcon | 2 | $27 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| Novartis | 1 | $17 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
| Coopervision Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,477 in reported general payments places this provider in the 70th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 23 | $18,564 |
| LumiganBimatoprost | 31 | $14,470 |
| Latanoprost | 171 | $3,624 |
| Timolol Maleate | 32 | $3,127 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $2,686 |
| Brimonidine Tartrate | 24 | $2,583 |
| Travoprost | 15 | $2,347 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,030 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 46 | $1,001 |
| Bimatoprost | 11 | $873 |
| Bacitracin | 11 | $859 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 21 | $846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $19 | $14,47031 claims |
| AlconSimbrinza | $27 | $2,03011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,743 optometrist providers in New York.
Other optometrist in Vestal
- Roy KlineLake Katrine$822K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$374K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
- Justin BazanBrooklyn$303K
- Jennifer TsaiNew York$275K
- Alexander KabiriQueens Village$268K
- Sophia VisanjiNew York$233K
- Jason ComptonNew York$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.